Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39…

Read More

Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that

[ad_1] Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments.  The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have…

Read More